Patent · US Expired

Method for finding nucleotide synthesis inhibitors having fewer side effects

US6716411B2 · kind B2 · utility

1Cited by

3References

5Claims

0Family size

Assignee

Aventis Pharma Deutschland GmbH · DE

Inventors

Jürgen Lindner · Worms, DE
Burkhard Haase · Hofheim, DE

Key dates

Filing date	Dec 13, 2000
Grant date	Apr 6, 2004
Priority date	—
Expiry date	Dec 13, 2020

Classification

Technology area (CPC G)Physics
CPC primaryG01N33/5088
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a method for finding nucleotide synthesis inhibitors which have a better therapeutic window. An efficacious dose of a nucleotide synthesis inhibitor is administered to a mammal. The concentration of the nucleotide synthesis inhibitor in the blood of the mammal is observed and it is determined whether the nucleotide synthesis inhibitor has a half-life which is shorter than that of N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide. The invention also relates to a method of using nucleotide synthesis inhibitors in the treatment of immunological diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.